Conex

Quick links to important sections

Conex

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Conex

Conex is a fixed-dose combination product classified pharmaceutically as an antihistamine-decongestant combination medicine, engineered for the symptomatic management of upper respiratory conditions. This oral medication is fundamentally a synthetic chemical compound, designed to address the dual pathology of allergic reactions and associated physical congestion through a single preparation.

Property Description
Active ingredient Dexbrompheniramine Maleate, Pseudoephedrine Hydrochloride
Form Oral Tablets (including Extended-Release), Oral Liquid Solutions
Pharmacological class Antihistamine-Decongestant Combination
Common use Symptomatic management of cold and allergy symptoms
Origin Synthetic chemical compounds

What Type of Medicine is Conex and How is it Classified?

Conex is categorized as an upper respiratory combination product intended for short-term relief where both histamine-related symptoms and congestion are present. The drug is classified as such because it features two distinct therapeutic actions in one formulation. This dual-action approach is clinically recognized for effectively mitigating allergic responses while simultaneously addressing nasal congestion. The product is often positioned for a general patient population experiencing typical symptoms such as seasonal hay fever or a persistent head cold.

Composition and Available Forms of Conex

The medication's composition is defined by its two main active ingredients [INN]: a first-generation antihistamine, typically Dexbrompheniramine Maleate, and the nasal decongestant Pseudoephedrine Hydrochloride. The Pseudoephedrine component is classified as an adrenergic alpha-agonist, reflecting its ability to cause vasoconstriction in the nasal passages. Conex is administered via the oral route and is distinctively available in multiple dosage form(s), including conventional oral tablets and specialized oral liquid solutions, ensuring accessibility for various patient groups.

General Purpose and High-Level Action

The general purpose of Conex is the symptomatic management of discomfort arising from irritated and congested mucous membranes. This is achieved through a high-level dual action: the antihistamine works to block the effects of allergy-causing chemicals (histamine), while the decongestant causes vasoconstriction, physically working to shrink nasal swelling and clear obstruction in the airways. The presence of a first-generation antihistamine also means the product assists in drying up nasal secretions, contributing to clearer breathing.

Regulatory References

  1. FDA-Approved Drug Labeling (DailyMed)

What side effects are possible with Conex?

Possible Side Effects and Safety Information

The officially documented adverse effects for Conex, a fixed-dose combination of an antihistamine (Dexbrompheniramine) and a decongestant (Pseudoephedrine), are primarily classified across various physiological systems. The most frequent adverse reactions documented in regulatory labeling are often related to the Central Nervous System (CNS) and Anticholinergic effects.

Classification Common/Frequent Adverse Reactions
CNS Effects Drowsiness, Dizziness, Nervousness, Insomnia, Headache
Anticholinergic Effects Dryness of mouth, nose, and throat; Thickening of bronchial secretions

Adverse effects are also categorized by System-Organ Class, including the Cardiovascular System (e.g., palpitation, hypertension), the Gastrointestinal System (e.g., nausea, constipation), and the Genitourinary System (e.g., difficulty urinating).

The regulatory safety profile notes specific, rare, but serious adverse reactions, including convulsions, certain cardiac arrhythmias, and severe hematologic disorders such as agranulocytosis. Exceeding the recommended dosage may increase the chance of experiencing side effects.

Population-Specific Safety Notes are defined in official labeling. Older adults are noted as being more susceptible to side effects like sedation, confusion, and urinary difficulty. Furthermore, the combination is contraindicated for use with, or within two weeks of stopping, a Monoamine Oxidase Inhibitor (MAOI), as explicitly stated in the prescribing information.

Overdose and Emergency Response

The official regulatory profile for a Conex overdose primarily describes symptoms associated with excessive central nervous system (CNS) and sympathetic stimulation. Manifestations may include convulsions, hallucinations, unusual nervousness, excitement, and confusion. The cardiovascular system may exhibit increased blood pressure or severe heart rhythm disturbances. Anticholinergic signs, such as dilated pupils, dry mouth, and inability to urinate, are also documented features of overdose.

Regulatory guidance requires immediate action. Individuals must seek professional assistance or contact a Poison Control Center immediately upon suspicion of overdose. Urgent medical attention is mandatory if symptoms of severe neurological events occur, such as a severe sudden headache or changes in vision, or if the individual collapses or has a seizure.

Management is focused on supportive measures, as no specific antidote is known. Officially described procedures include:

  • Use of activated charcoal or gastric lavage.
  • Continuous vital sign monitoring and diagnostic tests (e.g., ECG).
  • Specific treatments for symptomatic control, such as administering intravenous short-acting barbiturates for severe CNS hyperactivity or convulsive seizures.

Excitability during an overdose is a specific regulatory consideration for children.

Therapeutic Uses of Conex

What Conex Treats: Main Uses and Benefits

Conex is commonly used to assist with symptomatic relief in situations involving a combination of specific upper respiratory discomforts. The medication is generally used across conditions characterized by episodic or fluctuating symptom patterns, particularly hay fever (allergic rhinitis) and the common cold. This approach may be relevant when supportive symptom management is appropriate to help ease challenging symptoms that become more disruptive during flare-ups.

The medication is commonly used for managing symptoms of conditions characterized by episodic or fluctuating symptom patterns, which include persistent sneezing, frequent runny nose, itching of the nose and eyes, and the physical discomfort of nasal and sinus congestion.

“Conex is generally used across conditions presenting with acute episodes where multiple symptoms occur together.”

The medication is applied in clinical settings that involve acute or unstable symptom patterns, and may support the patient during difficult episodes while assisting with maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Support for Nasal Congestion and Allergic Irritation Symptoms

Regulatory References

  1. DailyMed overview provided by the NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Conex?

Eligibility for using Conex, a fixed-dose antihistamine-decongestant combination, is strictly defined by government regulatory labeling to minimize risk to specific populations. The use of this medicine is contraindicated for several groups due to potential severe adverse effects.

Absolute Contraindications

Conex must not be used by patients who have severe hypertension or severe coronary artery disease. It is also strictly prohibited for individuals who are currently taking Monoamine Oxidase Inhibitors (MAOIs) or have used them within the last 14 days. Other absolute contraindications include narrow-angle glaucoma, conditions causing urinary retention, and known hypersensitivity to the active ingredients. Breastfeeding mothers and children under two years of age must not use this medicine.

Restricted Use and Special Populations

Use is not recommended or requires special caution in several other populations. This includes patients with severe renal impairment or severe hepatic impairment. Older adults (65 years and over) should use Conex with caution due to increased susceptibility to effects on the central nervous and cardiovascular systems. Use during pregnancy, especially the third trimester, is generally not recommended according to official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents outline specific interaction patterns for Conex, a fixed-dose combination product containing an antihistamine and a decongestant.


Interaction Classifications and Restrictions

The most stringent restriction involves Monoamine Oxidase Inhibitors (MAOIs). Co-administration of Conex with an MAOI drug is strictly contraindicated as it can prolong and intensify the anticholinergic effects of the antihistamine component and enhance the effects of pseudoephedrine. A mandatory waiting period of two weeks after stopping any MAOI drug must pass before Conex administration is permitted.


Pharmacodynamic Effects

Documented pharmacodynamic interactions primarily involve additive effects on the central nervous system (CNS). CNS Depressants, including sedatives and tranquilizers, when co-administered, may produce an additive effect that increases drowsiness. Similarly, alcoholic beverages are restricted due to their potential to increase the drowsiness effect caused by the antihistamine component. Furthermore, the pseudoephedrine component may reduce the therapeutic effects of certain antihypertensive drugs, a known interaction documented in official prescribing information.

This profile is defined by prohibited combinations and cautions regarding additive and antagonistic effects, as stated by government regulatory authorities.

Mechanism of Action

Histamine Receptor Inhibition and Pathway Modulation

Dexbrompheniramine acts as a competitive antagonist at peripheral and central Histamine H1 receptors. This molecular interaction blocks the signaling cascade driven by endogenous histamine, thereby preventing increased capillary permeability and local vasodilation. This mechanism helps limit the histamine-mediated increase in tissue fluid volume and, due to central action, results in generalized central neuronal depression.

Sympathetic Adrenergic Activation and Vascular Tone Regulation

The decongestant component, Pseudoephedrine, engages the autonomic nervous system via mixed alpha1-adrenergic agonism. The stimulation of these receptors on vascular smooth muscle in the nasal mucosa causes vasoconstriction. This primary physiological consequence results in a decreased mucosal blood volume (hyperemia) and tissue size.

Mechanistic Synergy: Dual-Action Complementarity

The combination provides a synergistic approach where H1 blockade dampens the inflammatory stimulus that promotes fluid leakage, while alpha1 agonism promotes vascular smooth muscle contraction. The combined action achieves a simultaneous modulation of inflammatory signaling and vascular tone.

Dosage and Administration Information

How to Use Conex

Conex, a fixed-dose antihistamine-decongestant combination, is administered exclusively via the oral route in several labeled forms, including immediate-release tablets, extended-release tablets, and an oral liquid solution. The instructions for administration are defined to ensure standardized use.


Dosing and Administration Schedule

For immediate-release forms, the standard adult dose (ages 12 years and over) typically contains 2 mg of Dexbrompheniramine and 60 mg of Pseudoephedrine per unit. This dose is scheduled to be taken every 4 to 6 hours. Established guidelines specify that an individual must not exceed four doses within any 24-hour period. Specific age-group rules are established for pediatric patients; children aged 6 to under 12 years are instructed to use a reduced dose (e.g., half the adult dose) at the same frequency. Use in children under 6 years is generally advised against without specific direction.


Procedural Conditions and Duration

The medicine may be administered with or without food. Administration instructions specify procedural conditions tied to the proper use of different forms: extended-release tablets must be swallowed whole and must not be crushed, chewed, or broken; similarly, the liquid solution requires measurement using a calibrated dosing device. Conex is intended for short-term relief only, and labeling commonly advises against continuous use for longer than 7 days. If a dose is missed, the guidance is to skip the missed dose and continue with the next scheduled dose, thereby prohibiting the administration of a double dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Conex

The research base for Conex, which is a combination of two active ingredients, research has explored the combination of active ingredients through Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews that gather and analyze findings from multiple studies. Research studies monitored the combination product for patterns of change in symptoms over defined, typically short, periods. Studies help show what has been observed so far, focusing on group patterns rather than individual outcomes.


Evidence for Use in Seasonal Allergic Rhinitis (Hay Fever)

Clinical trials for this medicine were evaluated in short-term RCTs, where participants were randomly assigned to receive either the medicine, its individual components, or a placebo. This research was applied in studies examining patient-reported experiences related to physical discomfort from conditions characterized by fluctuating or episodic manifestations, such as hay fever. Outcomes related to symptoms like nasal congestion, running nose, sneezing, and itchy/watery eyes were measured using daily reflective symptom diaries.

Studies report how measurements of Total Symptom Scores and key individual symptoms like nasal blockage evolved in the observed populations during the study period. Findings describe patterns observed in the studies that were relevant in trials assessing short-term or episodic symptom patterns, with findings describe observed patterns in symptom severity measurements following the combination compared to placebo. What remains uncertain is the long-term effectiveness, as follow-up durations were limited, typically spanning no more than one to two weeks.


Evidence for Use in Common Cold Symptoms

Research exploring the use of this combination for common cold symptoms was studied in short-term RCTs during periods of increased symptom activity. Studies examined outcomes related to physical discomfort in conditions associated with acute or disruptive episodes, focusing primarily on symptoms of nasal congestion, runny nose, and sneezing. Systematic reviews of combination products examined measurements of change in nasal congestion scores in adults during the acute phase of the cold. Findings were mixed or inconsistent when research highlights changes measured during the study period for individual common cold symptoms beyond nasal congestion itself.


Evidence in Specific Patient Populations

Research examined the use of this combination in diverse groups, primarily focusing on Adults studied for symptom patterns. Studies explored the response in Adolescents and Older Children (typically 6 years and older) who experience seasonal allergic rhinitis or acute cold symptoms. However, findings for certain groups remain uncertain. The evidence base for this combination is notably insufficient concerning young children (under 6 years of age), as research focusing on this age group is limited. The results apply only to the populations studied.


What is Still Uncertain About Conex

There is limited information for long-term outcomes or the durability of the observed short-term changes. Furthermore, the certainty remains low when attempting to extrapolate study results to patient groups who were excluded from the original trials. Comparative evidence is lacking for how this specific combination performs against a wide array of newer-generation alternatives.

Key Studies & References

  1. First generation H1-antihistamines in the treatment of allergic rhinitis
  2. FDA Drug Labeling for Brompheniramine Maleate, Pseudoephedrine Hydrochloride Tablets (As an example of a related combination product monograph)

Frequently Asked Questions (FAQ)

Common questions about Conex (FAQ)


Q: Are there any non-prescription medicines that interact with Conex?

Official regulatory labels warn about combining Conex with any medicine that causes Central Nervous System (CNS) depression. This includes certain non-prescription drugs, which can lead to increased drowsiness. The label also specifies that combinations with products that may raise blood pressure are restricted.


Q: Are there any known food restrictions while taking Conex?

According to official product information, Conex may be taken with or without food. The only specific product restriction mentioned in the interaction documents relates to the consumption of alcoholic beverages.


Q: Is it possible to be allergic to the inactive ingredients in Conex?

Official contraindications for Conex specifically list hypersensitivity to the active ingredients. Regulatory agencies require a complete list of all active and inactive ingredients to be included on the official product label for consumer review.


Q: Why do some people report different effects from Conex?

Studies and official information indicate that individual responses to medication can vary. Research evidence summarizes patterns observed across large groups and notes that the results apply specifically only to the patient populations studied in clinical trials.


Q: Is the efficacy of Conex influenced by age or gender?

Official labeling addresses age-specific restrictions and cautions, particularly for young children and older adults regarding potential side effects. However, regulatory documents do not provide specific evidence on whether efficacy differences are influenced by gender.


Q: Is Conex used for other conditions besides the main approved use?

Regulatory documents limit the officially recognized use of Conex to the symptomatic management of cold and allergy symptoms. Official labeling does not address uses outside of this defined indication.


Q: Why is Conex sometimes mentioned in combination with another medicine?

Conex is structured as a fixed-dose combination product because the two active ingredients provide a dual-action approach. This is intended to block allergy effects while simultaneously reducing nasal swelling.


Q: Does the time of day matter for Conex's effectiveness?

The official regulatory label states that the medicine's schedule frequency is every 4 to 6 hours while limiting the maximum 24-hour dose. The labeling does not specify a difference in effectiveness based on the time of day (morning versus evening).


Q: Is Conex a controlled substance?

The pseudoephedrine component of Conex is a precursor chemical. Due to this composition, it is subject to specific federal sales and tracking regulations in the US, classifying it as a restricted over-the-counter (OTC) product.


Q: How long does it typically take to notice the full effects of Conex?

Although a precise onset time is not explicitly listed in the patient information, the medicine is scheduled for use every 4 to 6 hours for symptom relief. This frequency is consistent with drugs intended for short duration of action.


Q: Does Conex require a special prescription?

Conex is typically categorized as an Over-the-Counter (OTC) medicine. However, due to federal regulations concerning the pseudoephedrine component, its sales are restricted and tracked, often requiring presentation of identification at the point of purchase.


Q: Is there a generic version of Conex available?

Regulatory lists indicate that products containing the same two active ingredients, dexbrompheniramine maleate and pseudoephedrine hydrochloride, are available under various generic and brand names.


Q: Does Conex cause weight gain or loss?

According to the official documentation, observed side effects in clinical trials do not typically include weight gain or loss as a common or frequent adverse reaction for this specific combination product.


Q: Does Conex interact with supplements or herbal remedies?

Official regulatory documents do not list specific supplements or herbal remedies. However, the label specifies that combinations with products that cause Central Nervous System (CNS) depression or those that act as Monoamine Oxidase Inhibitors (MAOIs) are cautioned against.


Q: What should I generally expect if a mild side effect continues for several weeks?

Official labeling advises that the medicine is for short-term use only, typically less than 7 days. Patient information specifies that use should be stopped if symptoms or side effects persist or worsen beyond this recommended duration.


Q: Is Conex known to cause dependence or withdrawal symptoms?

Regulatory documents do not indicate that the product causes true physical dependence or withdrawal when used as directed. However, because of its decongestant ingredient, the pseudoephedrine component has a history of misuse potential and is subject to sale restrictions.


Q: How soon after stopping Conex does the substance clear the system?

Pharmacokinetic data in the regulatory label indicate that the drug's components are eliminated from the body through metabolic and excretory processes. The specific elimination half-lives are typically measured in hours.


Q: Are there specific lab tests needed before starting Conex?

Official labeling does not generally mandate specific laboratory tests prior to initiating use of this product. However, the label identifies patients with severe kidney or liver impairment as a group that requires caution.


Q: Can Conex be taken by people with lactose intolerance?

The inactive ingredients list for specific forms of Conex may include lactose or other excipients (inactive substances). The full, complete list of ingredients is always found on the official product label.


Q: How often is follow-up monitoring required when using Conex?

Since Conex is intended for short-term, symptomatic relief, official regulatory documents do not typically mandate routine clinical follow-up or monitoring for its specified use duration.


Q: Does Conex carry a Black Box Warning from the FDA?

Regulatory documentation does not feature a Black Box Warning for Conex. The label does, however, include safety warnings for rare but serious adverse reactions observed during use.


Q: What is the shelf life of Conex tablets?

The product's stability and expiration date (shelf life) are determined by the manufacturer based on regulatory testing. This information is required to be printed on the product packaging and the unit dose container.


Q: How is Conex typically packaged and sold?

Official labeling includes detailed information on how the product is supplied. This typically lists the National Drug Code (NDC), the quantity per package, and the type of container used for distribution.


Q: Is there an official patient guide for Conex?

Official regulatory documents include a required section titled 'Patient Counseling Information' or a Medication Guide. This provides simplified, key safety and usage information for the patient.

How should Conex be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory information requires Conex (Dexbrompheniramine Maleate and Pseudoephedrine Hydrochloride) to be stored at Controlled Room Temperature, specifically between 20^circ-25 C (68^circ-77 F). Storage environments with excess heat or excess moisture, such as a bathroom, are prohibited to maintain the drug’s stability.

Protection and Stability

  • The medication must be kept in its tightly closed original container.
  • Do not use the product if the tamper-evident seal or packaging is compromised.
  • It is mandatory to keep this and all drugs out of the sight and reach of children.

Disposal Rules

Unused or expired Conex should be discarded following specific government-issued instructions. The preferred method is returning the product to an authorized drug take-back program. If this is not possible, the medication must be mixed with an undesirable substance (e.g., used coffee grounds) in a sealed container before being placed in household trash. Do not flush Conex down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Conex found in:

A-Z Index: